Apoptosis in patients with primary antiphospholipid antibody syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-185X (Electronic) Linking ISSN: 17561841 NLM ISO Abbreviation: Int J Rheum Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Oxford, UK] : Wiley on behalf of the Asia Pacific League of Associations for Rheumatology
    • Subject Terms:
    • Abstract:
      Aim: Dysregulated apoptosis has been implicated in autoimmune diseases. In the present study, we investigated the apoptosis-related cytokines and apoptosis in patients with primary antiphospholipid syndrome (pAPS).
      Method: We prospectively recruited 12 pAPS patients, 17 antiphospholipid antibody (APA)-positive systemic lupus erythematosus (SLE) patients without APS manifestations (APA + SLE), 13 SLE patients with secondary APS (APS + SLE) and 10 healthy controls (HCs). Plasma levels of soluble apoptosis-inducing ligands and cytokines, and the expression levels of apoptosis-inducing ligands in peripheral blood mononuclear cells, were determined. In addition, blood lymphocytes/monocytes apoptosis were determined in six pAPS patients and six HCs, using flow cytometric analysis of caspase 3, 8 and 9 activities.
      Results: There was a trend toward higher plasma levels of soluble tumor necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL), interleukin-10 (IL-10) and TNF-α in pAPS patients when compared with HCs. We also observed higher plasma levels of IL-10 and TNF α in APA + SLE and APS + SLE patients when compared with HCs. However, there was no significant difference in blood lymphocytes/monocytes apoptosis between pAPS patients and HCs.
      Conclusion: There was a trend toward elevated plasma levels of sTRAIL, IL-10 and TNF-α, but no evidence for dysregulated apoptosis in pAPS patients.
      (© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
    • Grant Information:
      TCVGH-NCHU1057611 Taichung Veterans General Hospital and National Chung Hsing University
    • Contributed Indexing:
      Keywords: Fas ligand; antiphospholipid antibody syndrome; apoptosis; caspase; systemic lupus erythematosus; tumor necrosis factor-like weak inducer of apoptosis; tumor necrosis factor-related apoptosis-inducing ligand
    • Accession Number:
      0 (Apoptosis Regulatory Proteins)
      0 (Biomarkers)
      0 (Cytokines)
      0 (IL10 protein, human)
      0 (TNF-Related Apoptosis-Inducing Ligand)
      0 (TNFSF10 protein, human)
      0 (Tumor Necrosis Factor-alpha)
      130068-27-8 (Interleukin-10)
    • Publication Date:
      Date Created: 20190208 Date Completed: 20190903 Latest Revision: 20190903
    • Publication Date:
      20240105
    • Accession Number:
      10.1111/1756-185X.13468
    • Accession Number:
      30729698